Amylyx Pharmaceuticals, Inc. (AMLX)

Their mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and generally cannot regenerate. They are pursuing commercialization of their product candidate, AMX0035, which they believe is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. They submitted a New Drug Submission, or NDS, in Canada in the second quarter of 2021 for AMX0035 for the treatment of ALS and a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021. They also intend to submit a Marketing Authorization Application, or MAA, in Europe in the first quarter of 2022. The results of their Phase 2 clinical trial of AMX0035, known as the CENTAUR trial, were published in September 2020 in the New England Journal of Medicine and in October 2020 in the Journal of Muscle and Nerve and demonstrated functional and survival benefits for ALS patients. They believe AMX0035 has the potential to be a foundational therapy, meaning that it could be used alone or in conjunction with other therapies to change the treatment paradigm across a broad range of neurodegenerative diseases.

Industry
Pharmaceutical Preparations

CEO	CFO
-

Employees	Founded
110	2014

Address: 43 Thorndike St. Cambridge, Massachusetts 02141

Telephone: (617) 682-0917

Web page: http://www.amylyx.com

First Trade Date	1/7/2022
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the AMLX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Goldman Sachs

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Goldman Sachs/ SVB Leerink/ Evercore ISI
CO-Managers
H.C. Wainwright